The article provides an overview of the company and the power and application of our ENIGMAC drug discovery platform.
“We are really at the tip of the iceberg in terms of macrophage therapeutic discovery across multiple disease settings” said CEO Steve Myatt.“We’ve now completed the technical validation of our platform and are excited about the potential, for the first time, to be able truly interrogate macrophage disease biology at scale,” said CSO Carola Ries.
You can see the full article here.
